At this year’s Society for Neuroscience (SFN) conference in Chicago, Promega Corporation is showcasing its latest tool for researchers: the GloMax® Galaxy Bioluminescence Imager. This new device offers scientists a simpler way to observe low-expression protein targets in real time without needing to convert their bioluminescent assays into fluorescent systems—a step that’s typically necessary with traditional imaging methods.
“Researchers can now use the same NanoLuc-based technologies they’ve been working with in plate-based assays for imaging, without having to switch to fluorescence,” said Kristin Riching, Senior Research Scientist at Promega.
The GloMax® Galaxy is designed to work with Promega’s NanoLuc® luciferase chemistries, allowing scientists to track processes like protein interactions, degradation, and localization. It can also be used for studying ligand-protein interactions and targeted cell killing, among other applications.
One of the key advantages of bioluminescence imaging is that it doesn’t rely on external light sources like fluorescence imaging does. This means less background noise and fewer issues like photobleaching, which can damage cells or alter their behavior. The technology allows researchers to monitor cellular activity over longer periods without affecting the cells’ health, offering clearer insights into how proteins and cells function in real biological systems.
By eliminating the need for complex assay conversions, the GloMax® Galaxy could make it easier for scientists to conduct long-term studies in fields like disease modeling and drug testing.
Promega’s new imager is part of a broader range of tools designed to simplify research workflows. At the SFN conference, attendees can see live demonstrations of the GloMax® Galaxy at Promega’s booth (#1316) and learn more about its potential uses in their work.